# **Special Issue**

# Advancements in Synthetic Small Molecules as Anticancer Therapeutics

# Message from the Guest Editors

Cancer is the uncontrolled, rapid, and pathological proliferation of abnormal cells, which is a tremendous problem worldwide today. According to the World Health Organization (WHO), cancer is the second leading cause of death globally. Its treatment remains challenging for the scientific community. One major problem with its treatment is that most of the currently available drugs are unable to differentiate between normal and abnormal cells, which is the reason behind their side effects such as thrombocytopenia, anemia, delirium, edema, etc. Anticancer small molecules, also known as small molecule inhibitors, are a type of therapeutic agent used in cancer treatment. These molecules are small organic compounds that can penetrate cells and interact with specific targets involved in cancer cell growth and survival. They work by inhibiting or interfering with the activity of proteins or pathways that are essential for cancer cell proliferation. This Special Issue welcomes research and up-to-date review articles addressing current research on anticancer therapeutics, with a particular focus on discovering novel anti-cancer small molecules.

### **Guest Editors**

Dr. Amandeep Singh

Dr. Harbinder Singh

Dr. Anu Rani

## Deadline for manuscript submissions

closed (30 June 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/178174

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





# **About the Journal**

## Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).